TMO Thermo Fisher Scientific Inc.
Healthcare$448.28-0.24%ClosedMarket Cap: $166.59B
As of 2026-05-25
Valuation
P/E (TTM)
27.08
PEG
4.53
P/B
3.21
P/S
3.69
EV/EBITDA
18.50
DCF Value
$540.72
FCF Yield
4.1%
Div Yield
0.4%
Margins & Returns
Gross Margin
39.4%
Operating Margin
17.8%
Net Margin
15.2%
ROE
13.3%
ROA
6.1%
ROIC
7.3%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $11.01B | 40.7% | $1.86B | $1.65B | $— | $0.47 |
| Q4 null | $12.21B | 38.0% | $2.30B | $1.98B | $— | $0.43 |
| FY null | $44.56B | 37.7% | $8.11B | $6.74B | $— | $1.72 |
| Q3 null | $11.12B | 41.8% | $1.94B | $1.62B | $— | $0.43 |
| Q2 null | $10.86B | 37.3% | $1.92B | $1.62B | $— | $0.43 |
| Q1 null | $10.36B | 41.0% | $1.84B | $1.51B | $— | $0.43 |
| Q4 null | $11.39B | 39.2% | $2.27B | $1.83B | $— | $0.39 |
| FY null | $42.88B | 41.3% | $7.66B | $6.33B | $— | $1.56 |
| Q3 null | $10.60B | 41.0% | $1.92B | $1.63B | $— | $0.39 |
| Q2 null | $10.54B | 41.2% | $1.76B | $1.55B | $— | $0.39 |
| Q1 null | $10.35B | 40.8% | $1.72B | $1.33B | $— | $0.39 |
| Q4 2023 | $10.89B | 36.3% | $1.99B | $1.63B | $4.20 | $0.35 |